Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To define the role of the assessment of myocardial viability with dobutamine echocardiography (DE) in the clinical evaluation and selection of the best treatment for a high-risk subset of patients with coronary artery disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medstar Health Research Institute
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Dobutamine

Criteria

Enrollment Requirements

Inclusion Criteria:

• Symptomatic heart failure defined as NYHA Class II - IV (within 3 months of entry)

• LV less than 35% defined by CMR or gated SPECT studies

• Coronary anatomy suitable for revascularization

Exclusion Criteria:

• Primary valvular heart disease clearly defined indicating the need for valve repair or replacement

• Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support

• PCI planned for CAD treatment

• Acute myocardial infarction within 30 days

• More than one prior cardiac operation

• Non-cardiac illness with life expectancy of less than 3 years

• Non-cardiac illness imposing substantial operative mortality. Patients eligible to enter the study will be further evaluated by the STICH team for SVR eligibility.